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Dipeptidyl peptidase‑4 inhibitor 
protects against non‑alcoholic 
steatohepatitis in mice by targeting  
TRAIL receptor‑mediated 
lipoapoptosis via modulating  
hepatic dipeptidyl peptidase‑4 
expression
Minyoung Lee1,4, Eugene Shin2,4, Jaehyun Bae1, Yongin Cho3, Ji‑Yeon Lee1, Yong‑ho Lee1, 
Byung‑Wan Lee1, Eun Seok Kang1 & Bong‑Soo Cha1,2*
Dipeptidyl peptidase‑4 inhibitors (DPP4i) are antidiabetic medications that prevent cleavage 
of incretin hormones by dipeptidyl peptidase‑4 (DPP4). DPP4 is ubiquitously expressed, and its 
hepatic DPP4 expression is upregulated under non‑alcoholic steatohepatitis (NASH) conditions. 
We investigated the effect of DPP4i treatment on NASH pathogenesis, as well as its potential 
underlying molecular mechanisms. Mice were randomly divided into three groups: Group 1, chow‑
fed mice treated with vehicle for 20 weeks; Group 2, high‑fat, high‑fructose, and high‑cholesterol 
Amylin liver NASH (AMLN) diet‑fed mice treated with vehicle for 20 weeks; Group 3, AMLN diet‑fed 
mice treated with vehicle for the first 10 weeks, followed by the DPP4i teneligliptin (20 mg/kg/day) 
for additional 10 weeks. DPP4i administration reduced serum liver enzyme and hepatic triglyceride 
levels and markedly improved hepatic steatosis and fibrosis in the AMLN diet‑induced NASH model. 
In vivo, NASH alleviation significantly correlated with the suppression of tumor necrosis factor‑related 
apoptosis‑inducing ligand (TRAIL) receptor‑mediated apoptosis and downregulated hepatic DPP4 
expression. In vitro, DPP4i treatment significantly decreased the markers of TRAIL receptor‑mediated 
lipoapoptosis and suppressed DPP4 expression in palmitate‑treated hepatocytes. In conclusion, 
DPP4i may efficiently attenuate the pathogenesis of AMLN diet‑induced NASH in mice by suppressing 
lipotoxicity‑induced apoptosis, possibly by modulating hepatic DPP4 expression.
Non-alcoholic fatty liver disease (NAFLD) has emerged as a metabolic liver disorder affecting approximately 
one quarter of the world’s  population1. NAFLD encompasses a wide range of conditions, from simple steato-
sis to non-alcoholic steatohepatitis (NASH), the more aggressive form characterized by hepatic steatosis and 
inflammation due to the hepatocyte  injury2–4. NASH prevalence varies from 1.5 to 6.45% worldwide, and it is 
currently the second leading cause of cirrhosis among the adult population awaiting liver transplantation in the 
 US1,5. Thus, the development of effective therapeutic strategy to treat NASH is of great clinical interest. Several 
clinical trials have been recently conducted to evaluate pharmacotherapies for NASH; however, no medications 
have been approved to date by the US Food and Drug Administration (FDA)6.
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Dipeptidyl peptidase-4 inhibitors (DPP4i) are widely used oral antidiabetic medications that inhibit the 
degradation of incretin hormones including glucagon like peptide-1 (GLP-1). Treatment with these agents subse-
quently increases the glucose-dependent secretion of insulin, inhibits glucagon secretion, and slows down gastric 
 emptying7. As dipeptidyl peptidase-4 (DPP4) is ubiquitously expressed cell surface peptidase, modulation of its 
function may regulate not only glucose metabolism but may also have diverse systemic  effects8. Liver expresses 
and secretes DPP4, and the hepatic DPP4 expression levels are associated with a degree of hepatic steatosis in 
patients with  NASH9,10. Furthermore, in animal studies, an increase in the hepatic DPP4 expression level pro-
moted NAFLD  development11,12. Recently, several studies have reported regarding the therapeutic potential of 
DPP4i to treat NASH in animals and  humans13,14. However, the molecular mechanisms underlying the effects of 
DPP4i in NASH alleviation have not been elucidated. In particular, the role of hepatic DPP4 expression during 
the DPP4i-mediated NASH amelioration has not been concluded yet.
Lipotoxicity due to the elevated levels of cytotoxic saturated free fatty acids (FFAs) such as palmitate causes 
death of hepatocytes, a process termed as  lipoapoptosis15. Lipoapoptosis is a pathological hallmark of NASH, 
and it correlates with the disease  severity15,16. Increased endoplasmic reticulum (ER) stress caused by these 
cytotoxic lipids activates death receptors on the cell surface of  hepatocytes16. Among the death receptors, tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAIL-R2, also known as death receptor 5 
[DR5]) appears to be a major mediator of lipotoxicity in  hepatocytes15, inducing caspase-dependent hepatocyte 
 apoptosis17. Increased hepatic TRAIL-R2 expression, driven by lipotoxicity-stimulated ER stress, is mediated 
by the transcription factor CAAT/enhancer binding protein (C/EBP) homologous protein (CHOP)16, one of 
direct target genes of activating transcription factor 4 (ATF4)18–20. Interestingly, the ATF4-consensus site lies in 
the exon 1 of DPP4  gene21, suggesting a possible mechanistic link between hepatocyte DPP4 expression and the 
ER stress-induced lipoapoptosis in the liver. Furthermore, treatment with teneligliptin, a DPP4i, significantly 
reduced high glucose-induced expression of ER stress markers, including ATF4 and CHOP in endothelial cells 
in vitro22. However, the effect of DPP4i treatment on ER stress-mediated lipoapoptosis in NASH has never been 
investigated.
In the present study, we used high-fat, high-fructose, and high-cholesterol Amylin liver NASH (AMLN) 
diet to induce NASH in  mice23 and palmitate-stimulated hepatocytes. We investigated whether DPP4i could 
effectively alleviate the pathogenesis of NASH by regulating hepatic DPP4 expression and lipotoxicity-induced 
apoptosis using in vivo and in vitro models.
Results
DPP4i improves biochemical indices and reduces liver fibrosis and pro‑inflammatory marker 
expression in the AMLN diet‑induced mouse model of NASH. We evaluated the characteristic fea-
tures such as body weight and biochemical indices, in response to the AMLN diet and DPP4i administration in 
male C57BL/6J mice at 20th week (Table 1). Vehicle-treated AMLN-fed mice exhibited a significant increase in 
body weight and liver to body weight ratio compared with the chow-fed mice (Table 1 and Fig. 1c). The levels of 
serum total cholesterol, FFAs, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were also 
significantly higher in the vehicle-treated AMLN-fed mice than in the chow-fed mice (all p < 0.05). Administra-
tion of DPP4i significantly reduced the body weight, liver to body weight ratio, and the levels of serum total cho-
lesterol, FFAs, AST, and ALT in the AMLN-fed mice (all p < 0.05). Daily food intake, body weight, and random 
glucose values during the all experimental course are summarized in Supplementary Figure S1b–d. 
DPP4i alleviates the pathogenesis of NASH in the AMLN diet‑induced mouse model. Histo-
logical assessment of hepatic steatosis was performed on the hematoxylin and eosin (H&E)-stained tissue sec-
tions, and hepatic fibrosis was evaluated using the Masson’s trichrome (MT)-stained tissue sections (Fig. 1a,b). 
NAFLD activity score was also assessed using the histological H&E-stained tissue sections (Table 2). H&E stain-
Table 1.  Characteristic features of body weight and biochemical indices according to the AMLN diet and 
DPP4i administration at 20th week. Data are presented as mean ± SEM. *p < 0.05 versus vehicle-treated chow-
fed mice. #p < 0.05 versus vehicle-treated AMLN-fed mice. Chow, vehicle-treated chow-fed mice; AMLN, 
vehicle-treated AMLN-fed mice; AMLN + DPP4i, DPP4i-treated (teneligliptin 20 mg/kg of body weight/day by 
oral gavage for 10 weeks) AMLN-fed mice. ALT, alanine aminotransferase; AMLN, Amylin liver NASH model 
diet; AST, aspartate aminotransferase; DPP4i, dipeptidyl peptidase-4 inhibitors; NAFLD, non-alcoholic fatty 
liver disease.
Chow AMLN AMLN + DPP4i
N = 10 N = 13 N = 10
Body weight (g) 28.1 ± 1.4 39.4 ± 2.1* 35.1 ± 2.9*#
Fasting serum glucose (mg/dL) 156 ± 32 165 ± 36 172 ± 34
Fasting serum insulin (ng/dL) 0.33 ± 0.27 0.25 ± 0.06 0.24 ± 0.04
Serum total cholesterol (mg/dL) 72 ± 7 176 ± 59* 127 ± 40*#
Serum free fatty acids (mM) 0.18 ± 0.04 0.65 ± 0.17* 0.43 ± 0.13*#
Serum triglyceride (mg/dL) 89 ± 29 38 ± 17* 25 ± 6*#
Serum AST (IU/L) 86 ± 47 287 ± 162* 161 ± 60*#
Serum ALT (IU/L) 23 ± 4 347 ± 292* 142 ± 121*#
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ing revealed an increase in steatosis, lobular inflammation, and hepatocyte ballooning in the vehicle-treated 
AMLN-fed mice compared with the chow-fed mice. Treatment with DPP4i significantly improved the histo-
pathological liver damage and NAFLD activity score in the AMLN-fed mice (Fig. 1a and Table 2). The MT-
stained tissue sections revealed that hepatic fibrosis was progressed in the AMLN-fed mice, and DPP4i admin-
istration improved fibrosis (Fig. 1b). Increased hepatic triglyceride (TG) levels in the AMLN-fed mice were also 
significantly reversed by the DPP4i treatment (Fig. 1d, p  < 0.01).
We analyzed the mRNA expression of collagen type 1 α1 (collagen1α1) and α-smooth muscle actin (αSMA), 
the markers of fibrosis, and transforming growth factor-1 β (TGF-1β) and monocyte chemoattractant protein-1 
(MCP-1), the pro-inflammatory markers, in the liver (Fig. 1e–h). The levels of fibrotic and pro-inflammatory 
markers were significantly higher in the vehicle-treated AMLN-fed mice than in the chow-fed mice (all p < 0.05). 
DPP4i treatment reduced liver fibrosis and the expression levels of pro-inflammatory markers in the AMLN-fed 
mice (all p < 0.05).
DPP4i downregulates hepatic DPP4 expression and attenuates TRAIL‑R2‑mediated apoptosis 
in the AMLN diet‑induced mouse model of NASH. We measured the hepatic mRNA and protein lev-
els of DPP4 (Fig. 2a,b), as hepatic DPP4 was previously shown to be elevated during  NASH10,24. In comparison 
with the chow-fed mice, vehicle-treated AMLN-fed mice showed upregulated mRNA and protein expression of 
DPP4 in the liver; however, their expression was downregulated by the DPP4i treatment. As the ATF4-consensus 
site in the exon 1 of DPP4 gene was previously  identified21, we analyzed the mRNA expression of ATF4 and its 
downstream target, CHOP (Fig. 2c,d). Consistent with the DPP4 mRNA expression results, ATF4 and CHOP 
mRNA expression levels were higher in the vehicle-treated AMLN-fed mice than in the chow-fed mice, and 
DPP4i treatment attenuated these changes (all p < 0.05).
To investigate whether the increase in the ER stress markers (ATF4 and CHOP) causes ER stress-mediated 
apoptosis, we evaluated TRAIL-R2 mRNA levels and caspase 3/7 activity in the liver tissues (Fig. 2e,f). Vehicle-
treated AMLN-fed mice showed a prominent increase in the TRAIL-R2 expression levels and caspase 3/7 activity 
compared with the chow-fed mice (all p < 0.01). Consistent with the effects on ER stress markers, DPP4i attenu-
ated TRAIL-R2 expression and caspase 3/7 activity in the liver of AMLN-fed mice. Interestingly, the relative 
TRAIL-R2 mRNA expression significantly correlated with NAFLD activity score (Fig. 2g, p < 0.01), suggesting 
that the death receptor signaling via TRAIL-R2 plays a key role in the pathogenesis of AMLN diet-induced 
NASH. Furthermore, the expression of DPP4 mRNA significantly correlated with TRAIL-R2 expression levels, 
biochemical indices, and NAFLD activity score (Fig. 2h and Table 3). Even after adjustment for confounding 
biochemical indices, the relative DPP4 mRNA expression level was a significant determinant factor for a higher 
NAFLD activity score (Table 4). 
We performed TUNEL assay to count apoptotic cell number in the livers of AMLN-fed and chow-fed mice 
(Supplementary Figure S2). The vehicle-treated AMLN-fed mice showed a six-fold greater increase in the number 
of TUNEL-positive cells in the liver than the chow-fed mice, and DPP4i treatment significantly reduced that 
number (Supplementary Figure S2b, p < 0.01).
DPP4i treatment exerts protective effects against lipoapoptosis in hepatocyte. Next, we eval-
uated the effect of DPP4i treatment on DPP4 expression, ER stress markers, and TRAIL-R2-mediated apoptosis 
using HepG2 cells (Fig. 3). Palmitate-treated hepatocytes showed a significant increase in DPP4, ATF4, and 
CHOP mRNA expression levels, as well as DPP4 protein expression level (Fig. 3a–d). Treatment with DPP4i 
significantly attenuated the increased mRNA and protein levels of DPP4 as well as the mRNA levels of ATF4 
and CHOP in the palmitate-treated hepatocytes. Palmitate treatment also increased the mRNA and protein 
levels of TRAIL-R2 and effector caspase 3/7 activity in hepatocytes, thereby promoting apoptosis via TRAIL-R2 
(Fig.  3e–g). TRAIL-R2 expression and caspase 3/7 activity, the hallmarks of TRAIL-R2-mediated apoptosis, 
were markedly suppressed by the DPP4i treatment. The mRNA expressions of collagen1α1 and αSMA were also 
significantly increased by palmitate treatment (Fig. 3h,i, all p < 0.01), and this effect was significantly reduced 
by DPP4i (all p < 0.05). To evaluate whether DPP4i suppresses TRAIL-R2-mediated lipoapoptosis in general 
or palmitate-activated specific conditions, we cultured hepatocytes with recombinant human TRAIL protein 
(Supplementary Figure S3). The addition of TRAIL markedly increased caspase 3/7 activity in a dose dependent 
manner, and the DPP4i treatment significantly attenuated these changes (Supplementary Figure S3a). Similar to 
caspase 3/7 activity results, cell viability analyzed using the CCK8 assay showed a gradually decreasing trend in a 
TRAIL concentration-dependent manner. Administration of DPP4i significantly improved cell viability at high 
TRAIL concentration (Supplemental Figure S3b).
Taken together, these results indicate that DPP4i treatment may suppress DPP4 expression, as well as TRAIL-
R2-mediated lipoapoptosis, in hepatocytes, suggesting that DPP4 expression is associated with TRAIL-R2-me-
diated lipoapoptosis.
DPP4i treatment is associated with improvement in brown adipose tissue function and 
decreased visceral adipose tissue inflammation. The extrahepatic effect of DPP4i on adipose tissue 
in vivo was also evaluated to explain the preventive effect of DPP4i on body weight  gain25,26. To examine brown 
adipose tissue (BAT) function, BAT weights and mRNA expression of BAT thermogenic markers including 
uncoupling protein-1 (UCP-1), PPAR-γ coactivator 1-alpha (PGC1α), and transcriptional regulator PR domain 
containing 16 (PRDM16), were evaluated (Supplementary Figure S4a,b)25. UCP-1 expression was significantly 
downregulated in the vehicle-treated AMLN-fed mice compared with the chow-fed mice (p = 0.018). The expres-
sion levels of PGC1α and PRDM16 were decreased in the vehicle-treated AMLN-fed mice compared with the 
chow-fed mice without statistical significance. DPP4i treatment significantly increased the expression levels of 
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UCP-1 and PGC1α in the AMLN-fed mice. We also evaluated the mRNA expression of adipose tissue inflam-
matory markers such as interleukin (IL)-6, MCP-1, and TNF-α using the perirenal visceral adipose tissue (VAT; 
Supplementary Figure S4c)21. The levels of all these markers were significantly elevated in the vehicle-treated 
AMLN-fed mice compared with the chow-fed mice. DPP4i administration significantly decreased IL-6 level in 
the AMLN-fed mice (p = 0.015). MCP1 and TNF-α levels were also decreased by DPP4i in the AMLN-fed mice, 
even though statistical significance was not achieved. Collectively, DPP4i treatment partially contributed to the 
improvement of BAT function and decreased VAT inflammation in the present study, potentially providing an 
explanation for the attenuated body weight gain in the AMLN-fed mice.
Discussion
There is a clinical need to develop a potential therapeutic candidate to treat NASH. In the present study, we dem-
onstrated that the administration of DPP4i ameliorated the pathogenesis of NASH in the AMLN diet-induced 
mouse model, suppressed lipoapoptosis, and downregulated hepatic DPP4 expression.
DPP4i are useful antidiabetic medications considered to exert pleiotropic metabolic effects including amelio-
ration of  NASH8. The potential nonglycemic actions of DPP4i in diverse biological physiologies may be attributed 
to the ubiquitous expression of DPP4 in various  organs27. DPP4 is a 110-kDa membrane-associated peptidase 
that also exists in a slightly smaller, soluble  form28. DPP4 is expressed in all organs including the small intestine, 
biliary tract, and exocrine pancreas, while the liver is one of the organs with high expression of  DPP427,29,30. In 
previous reports, hepatic DPP4 expression was significantly higher in patients with NAFLD than in the healthy 
 controls24, and correlated with the histopathologic grade of  NASH10. These results indicate that hepatic DPP4 
expression may increase in response to metabolically toxic stimuli, thereby contributing to NASH development. 
In the present study, we confirmed the upregulation of hepatic DPP4 expression both in vivo (in the AMLN 
diet-induced NASH mouse model) and in vitro (in palmitate-stimulated HepG2 cells).
The increase in hepatic DPP4 expression may contribute to liver injury during NASH development in several 
ways. Previous reports have mainly focused on the increased lipogenesis in the liver associated with upregulated 
DPP4  expression27,31. Mice and rats lacking DPP4 activity exhibited decreased levels of hepatic sterol regulatory 
element-binding transcription factor 1-c (SREBP-1c) and fatty acid synthase (FAS)  expression32,33. The admin-
istration of DPP4i inhibited hepatic lipogenic gene expression and enhanced AMP-activated protein kinase 
(AMPK) activity in ob/ob and diet-induced NAFLD mouse  models14,34,35. Other researchers reported that DPP4i 
downregulated leukocyte cell-derived chemotaxin 2 (LECT2) expression in the livers of high fat diet-fed  mice36. 
As LECT2 induces SREBP-1c cleavage, and lipid accumulation, DPP4i-treated mice showed improved hepatic 
steatosis. However, modulation of lipogenesis is not sufficient to explain the whole mechanisms underlying the 
protective effects of DPP4i against NASH, as the development of steatosis is a benign and reversible state and 
requires triggering of different inflammatory signals to transform into  NASH37. The activation of inflammation-
mediated cells such as Kupffer cells and hepatic stellate cells (HSCs) plays an important role in the transition from 
steatosis and NASH via the pro-inflammatory and pro-fibrotic factors, including TNFα, TGF-β, collagen1α1, 
and αSMA38,39. In the present study, we sacrificed one mouse each from the control and the AMLN-fed groups at 
10th weeks of diet administration to assess liver histopathology before proceeding with the DPP4i administration 
and found that 10 weeks of AMLN diet maintainance had already induced hepatic steatosis and inflammation 
Figure 1.  DPP4i ameliorates histopathological phenotype of NASH and reduces fibrotic and pro-inflammatory 
markers in the AMLN diet-induced NASH mouse model. Representative histopathological images of H&E 
staining (a) and MT staining (b) in vehicle-treated chow-fed mice, vehicle-treated AMLN-fed mice, and DPP4i-
treated AMLN-fed mice (200 × magnification, scale bar: 200 μm). Graphs showing liver to body weight ratio (c), 
hepatic triglycerides level (d), and relative mRNA expression levels of collagen1α1 (e), αSMA (f), TGF-β1 (g), 
and MCP-1 (h) by qPCR according to the diet type and DPP4i administration at 20th week. Data in all graphs 
are presented as mean ± SEM. *p < 0.05; **p < 0.01; NS, not statistically significant. Chow, vehicle-treated chow-
fed mice; AMLN, vehicle-treated AMLN-fed mice; AMLN + DPP4i, DPP4i-treated (teneligliptin 20 mg/kg of 
body weight/day by oral gavage for 10 weeks) AMLN-fed mice.
▸
Table 2.  Characteristic features of liver pathology and NAFLD activity score according to the AMLN diet 
and DPP4i administration at 20th week. Data are presented as mean ± SEM. *p < 0.05 versus vehicle-treated 
chow-fed mice. #p < 0.05 versus vehicle-treated AMLN-fed mice. Chow, vehicle-treated chow-fed mice; AMLN, 
vehicle-treated AMLN-fed mice; AMLN + DPP4i, DPP4i-treated (teneligliptin 20 mg/kg of body weight/day 
by oral gavage for 10 weeks) AMLN-fed mice. AMLN, Amylin liver NASH model diet; DPP4i, dipeptidyl 
peptidase-4 inhibitors; NAFLD, non-alcoholic fatty liver disease.
Chow AMLN AMLN + DPP4i
N = 10 N = 13 N = 10
Steatosis 0.7 ± 0.5 2.8 ± 0.4* 1.9 ± 0.9*#
Lobular inflammation 0.1 ± 0.3 1.8 ± 0.6* 1.1 ± 0.7*#
Hepatocyte ballooning 0.8 ± 0.4 1.6 ± 0.5* 1.3 ± 0.5*
NAFLD activity score 1.6 ± 0.7 6.2 ± 1.3* 4.3 ± 1.9*#
6
Vol:.(1234567890)




Scientific Reports |        (2020) 10:19429  | https://doi.org/10.1038/s41598-020-75288-y
www.nature.com/scientificreports/
(Supplementary Figure S1e). Thus, our results indicate that the beneficial effects of DPP4i on NASH may be 
attributed not only to the suppression of hepatic lipogenesis before the development of hepatic steatosis but also 
to the protection against the progression of hepatic inflammation and fibrosis, even when the early pathological 
changes of NASH have already been induced. We also demonstrated the DPP4i-mediated reduction of pro-
inflammatory and pro-fibrotic factors in vivo and in vitro, indicating that DPP4i modified NASH progression 
beyond the regulation of steatosis.
Increased DPP4 expression levels in hepatocytes could be responsible for promoting intracellular ER stress 
through several pathways and DPP4i might suppress these pathways. Overexpression of hepatic DPP4 upregu-
lated lipogenic gene expression with lipid accumulation, resulting in increased intracellular ER  stress11,40,41. 
Furthermore, the hepatic DPP4 overexpression leads to further increase of intracellular ER stress by inhibiting 
the hepatocyte nuclear factor 1b (HNF1b)-associated suppression of superoxide  generation40. Similar to our 
Figure 2.  DPP4i decreases hepatic DPP4 expression and attenuates TRAIL-R2-mediated apoptosis in the 
AMLN diet-induced NASH mouse model. Graphs showing liver DPP4 mRNA levels (a) by qPCR and protein 
level (b) by western blot according to the diet type and DPP4i administration. Relevant bands from different 
western blots were cropped and grouped together. Original blots are shown in Supplementary Figure S5. Graphs 
showing relative mRNA expression levels of ATF4 (c), CHOP (d), and TRAIL-R2 (e) determined by qPCR 
according to the diet type and DPP4i administration. A graph showing liver caspase 3/7 activity (f) according 
to the diet type and DPP4i administration. Correlation plots between relative TRAIL-R2 mRNA levels and 
NAFLD activity score (g), and between relative mRNA levels of DPP4 and TRAIL-R2 (h). Data in all graphs are 
presented as mean ± SEM. *p < 0.05; **p < 0.01; NS, not statistically significant. Chow, vehicle-treated chow-fed 
mice; AMLN, vehicle-treated AMLN-fed mice; AMLN + DPP4i, DPP4i-treated (teneligliptin 20 mg/kg of body 
weight/day by oral gavage for 10 weeks) AMLN-fed mice; NAS, NAFLD activity score.
◂
Table 3.  Correlation between the relative DPP4 mRNA expression levels, biochemical indices, and the 
NAFLD activity score. Data are presented as Spearman’s rank correlation coefficient (r). p < 0.05 was regarded 
as statistically significant. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DPP4, dipeptidyl 





Body weight (g) 0.51 < 0.01
Liver weight (g) 0.57 < 0.01
Liver to body weight (%) 0.57 < 0.01
NAFLD activity score 0.55 < 0.01
Hepatic triglyceride (mg/g) 0.64 < 0.01
Fasting serum glucose (mg/dL) 0.16 0.42
Fasting serum insulin (ng/dL) 0.08 0.67
Serum total cholesterol (mg/dL) 0.56 < 0.01
Serum free fatty acids (mM) 0.40 0.05
Serum AST (IU/L) 0.70 < 0.01
Serum ALT (IU/L) 0.63 < 0.01
TRAIL-R2 mRNA 0.63 < 0.01
Table 4.  Relative DPP4 mRNA expression as a determinant factor for a higher NAFLD activity score. Multiple 
linear regression analysis was performed. Bold represent statistically significant values (p < 0.05). ALT, alanine 




Regression coefficient SE p-values
Body weight (g) 0.302 0.056  < 0.001
Serum fasting glucose (mg/dL) − 0.009 0.007 0.888
Serum AST (IU/L) − 0.002 0.006 0.708
Serum ALT (IU/L) < 0.001 0.003 0.946
DPP4 mRNA expression 1.903 0.557 0.003
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findings, DPP4i significantly alleviated ER stress indicators in both high fat diet- and methionine/choline-
deficient diet-induced NASH mouse models in previous  studies42,43.
In addition to hepatocytes, the protective effect of DPP4i against NASH might also be mediated by the modu-
lation of HSCs. Liver fibrosis of NASH is characterized by the excessive accumulation of extracellular matrix, as 
well as activated HSCs expressing DPP4 on its  surface44,45. Interestingly, the DPP4 expression was only observed 
in the activated, but not in the quiescent HSCs, indicating that it might play a role in HSC  activation45. Indeed, the 
use of DPP4i markedly inhibited liver fibrosis development via the suppression of HSC proliferation and collagen 
 synthesis45. Thus, DPP4i treatment-induced improvement of NASH and decreased hepatic DPP4 expression in 
our in vivo model might be driven not only from the effect on the hepatocytes but also from that on the HSCs.
To the best of our knowledge, this is the first study to investigate the protective effects of DPP4i on NASH in 
the context of TRAIL-R2-mediated lipoapoptosis. Hepatic lipotoxicity is a cardinal feature of  NASH17. Hepatocyte 
injury caused by FFAs contributes to hepatocyte apoptosis, which can also be referred as  lipoapoptosis46. Hepato-
cyte apoptosis is the most common and best-characterized cell death pathway in  NASH17 and is considered to 
be the cellular mechanism that distinguishes NASH from  steatosis17,46,47. The magnitude of hepatocyte apoptosis 
correlates with the severity of inflammation and fibrosis in  NASH47. Death receptor signaling via TRAIL-R2 has 
emerged as a key mechanism underlying hepatocyte lipoapoptosis in  NASH17. TRAIL-R2-mediated hepatocyte 
apoptosis is closely related to persistent ER stress induced by  FFAs17,19. Under sustained ER stress, the expression 
of ATF4 is upregulated, leading to CHOP  transcription48, and subsequent increased expression of TRAIL-R2, 
one of the important downstream target genes of  CHOP17,19. Enhanced TRAIL-R2-mediated apoptotic signaling 
during ER stress contributes to pro-inflammatory responses by various  chemokines15. DPP4 may be involved in 
the TRAIL-R2-mediated apoptotic cascades in relation to ER stress, considering the association between DPP4 
and intracellular ER stress. Meanwhile, based on our in vitro results obtained from the TRAIL-treated hepato-
cytes, it is also possible that there is a direct interaction between DPP4 and the TRAIL signaling pathways, and 
DPP4i treatment suppresses this interaction. As the activation of TRAIL signaling pathway causes mitochondrial 
dysfunction, intracellular reactive oxygen species (ROS) generation, and increased ER stress in  return16,47, the 
inhibition of TRAIL signaling pathway by modulating its interaction with DPP4 may result in the downregula-
tion of this vicious cycle. To elucidate a pathophysiological association between DPP4 and the TRAIL signaling 
pathway, further studies should be conducted.
Although DPP4 inhibitors were developed to suppress the plasma activity of DPP4, they may also downregu-
late the expression of DPP4 in other organs. For example, in the kidney of diabetic mice, the membrane-bound 
DPP4 and the cell surface protein integrin β1 are known to interact to induce the formation of TGF-β receptor 
heterodimer, thereby promoting kidney  fibrosis49. Treatment with DPP4i inhibited interaction between mem-
brane-bound DPP4 and integrin β1 and decreased renal DPP4 expression levels in the diabetic kidney mouse 
model, possibly by suppressing the endothelial-to-mesenchymal transition pathway  loop49. In the present study, 
the increased levels of hepatic DPP4 might have induced the ER stress-driven TRAIL signaling  pathway11,40,41 
and the enhanced TRAIL-R-induced apoptotic pathway could have further augmented ER stress by upregulat-
ing  ATF416,47. As a result, DPP4 expression would have been subsequently increased in a positive feedback loop 
of ER stress, in response to the possible transcriptional upregulation by  ATF421. DPP4i, in turn, may block this 
feedback loop, alleviating both TRAIL-R-induced apoptosis and DPP4 expression in NASH. Similar downregula-
tion of hepatic DPP4 expression by DPP4i was also reported in another study with using NASH animal  model43.
The AMLN diet used in the present study has higher proportions of fructose and trans-fat compared with 
the conventional high-fat diet. As a result, the AMLN diet induces NASH development more effectively, along 
with augmented ER stress and TRAIL signaling pathway, than the conventional high-fat diet. Fructose metabo-
lism in liver leads to a transient fall in adenosine triphosphate (ATP) levels, which does not occur during glu-
cose  metabolism50. This decrease in ATP levels induces oxidative stress, mitochondrial dysfunction, and uric 
acid generation, resulting in increased lipid accumulation, ER stress, and NAFLD  development50. A deletion of 
TRAIL prevented NAFLD development in mice fed with high-fructose diet, indicating that the high fructose-
induced hepatic steatosis and inflammation might be largely mediated by the TRAIL signaling  pathway51. In 
addition, current ample of evidence supported that the addition of cholesterol and trans-fatty acids to the diet 
are critical factors for steatohepatitis progression to  fibrosis52. Consumption of trans-fats causes proinflamma-
tory cytokine production by monocytes/macrophages, marked hepatic lipid accumulation, and an accretion of 
lipotoxic metabolites in the liver, reflecting mitochondrial metabolic  overload53–55. These changes consequently 
lead to ROS production and oxidative damage followed by the TRAIL-induced apoptosis in  hepatocytes16,56. 
Meanwhile, the AMLN diet was reported to have a minimal effect on serum glucose  level23,57. Hence, the effects 
Figure 3.  DPP4i treatment protects against lipoapoptosis in hepatocyte. Graphs showing relative mRNA levels 
of (a) DPP4 by qPCR (n = 6) and (b) protein level of DPP4 by western blot according to palmitate and DPP4i 
treatment. Relevant bands from different blots were cropped and grouped together. Original blots are shown 
in Supplementary Figure S6. Graphs showing relative mRNA levels of ER stress markers (c) ATF4, (d) CHOP 
(n = 6 per each marker), and (e) TRAIL-R2 (n = 8) by PCR, and (f) protein level of TRAIL-R2 (death receptor 
5, DR5) by western blot according to palmitate and DPP4i treatment. Relevant bands from different blots 
were cropped and grouped together. Original blots are shown in Supplementary Figure S7. Graphs showing 
(g) caspase 3/7 activity (n = 5), and relative mRNA expression levels of (h) collagen1α1 (n = 5), and (i) αSMA 
(n = 5) by qPCR according to palmitate and DPP4i treatment. Data in all graphs are presented as mean ± SEM. 
*p < 0.05; **p < 0.01; NS not statistically significant. Control, HepG2 cells, no treatment; Palmitate, HepG2 cells 
treated with palmitate (0.6 mM) for 18 h; Palmitate + DPP4i, HepG2 cells treated with teneligliptin (3 μM) for 
6 h, followed by palmitate treatment (0.6 mM) for 18 h. Each experiment was repeated as a described number of 
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of DPP4i on AMLN diet-induced NASH model might be exerted through glucose-independent mechanisms 
against ER stress and TRAIL-R2-mediated apoptotic pathway.
In the in vivo model used in this study, the extrahepatic effect of DPP4i on adipose tissues might explain the 
preventative effects of DPP4i on body weight gain, indirectly contributing to the amelioration of NASH. Similar 
to our results, DPP4i treatment attenuated body weight gain in previous animal  studies25,26. DPP4 is expressed 
in adipose tissue, and it is now considered a novel adipokine that may negatively affect insulin  senstivity58,59. 
DPP4 expression was positively correlated with the body mass index (BMI) and VAT, and the circulating DPP4 
positively correlated with the amount of VAT, adipocyte size, and adipose tissue  inflammation58. Thus, the inhi-
bition of DPP4 might induce body weight reduction via ameliorating inflammation and insulin resistance in 
adipocytes. Furthermore, this inhibition of DPP4 may be associated with increased energy expenditure through 
the activation of BAT  function25. Soluble DPP4 suppresses β-adrenoreceptor-stimulated UCP-1 expression in 
adipocytes, and this suppression was prevented by DPP4i  treatment25. In the present study, DPP4i improved BAT 
function and VAT inflammation, but the effect was marginally significant. The lesser effect of DPP4i on adipose 
tissue in the present study compared with that in the previous studies may be due to the difference in the diet 
type used in animal models. As the proportion of fat in total diet kcal affects weight  gain60, the AMLN diet might 
demonstrate a smaller effect on body weight gain and adiposity as a result of its relatively low fat composition 
(45% kcal fat) compared with the conventional high-fat diet (60% kcal fat) commonly used in the obesity animal 
models. Thus, in our diet model, the effects of DPP4i on adipose tissue might be diminished compared with the 
previous  reports25,26. Although we did not investigate in this study, DPP4i may exert its preventive effects against 
body weight gain and NAFLD, potentially by playing a role in the gut. DPP4i promoted macrophage-to-feces 
reverse cholesterol transport and reduced intestinal cholesterol absorption in an obese mice  model61. DPP4i also 
exhibited beneficial effects at the intestinal level by modulation of gut microbiota and preservation of ileal crypt 
depth, thereby decreasing the levels of hepatic proinflammatory  cytokines62.
We observed significant differences in body weight between vehicle-treated and DPP4i-treated AMLN-fed 
groups at 7th and 8th weeks; it might be due to the metabolically healthier innate traits of mice in the DPP4i-
treated AMLN-fed group than of those in the vehicle-treated AMLN-fed group owing to individual variations 
within the species. However, there was no significant difference in the body weights between the two groups at 
9th week, a week prior to the start of DPP4i administration. Thus, we presumed that the metabolic variations 
between the two groups would not have been considerably different to affect the current results.
In the current study, we found that DPP4i could effectively ameliorate the pathogenesis of NASH in a mouse 
model; however, previous human studies failed to show consistent results when treating NASH with  DPP4i13,63,64. 
This discrepancy could result from the difference between the species such as mice and human. Another expla-
nation is the dose of teneligliptin used in the current study: it was higher compared with the clinically used 
human dose (after the drug dose conversion between mice and human is calculated)65. Considering our data, to 
exert beneficial effects on NASH by DPP4i in humans, higher doses than the conventionally used clinical dose 
of DPP4i might have to be administered. Differences in several important confounding factors such as food 
intake, BMI, and glucose levels between previous human studies could also contribute to inconsistent results. 
Future well-designed human clinical trials with sufficient number of subjects and with various doses of DPP4i 
are necessary to prove their effects on NASH.
In conclusion, we demonstrated that DPP4i alleviated the pathogenesis of AMLN diet-induced NASH in a 
mouse model through the suppression of lipoapoptosis, possibly by regulating hepatic DPP4 expression. The 
in-depth mechanism linking hepatic DPP4 and lipoapoptosis needs further investigation to develop an effective 
therapeutic strategy for NASH.
Materials and methods
Animal experiments. Six-week-old male C57BL/6J mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME, USA). After a 1-week acclimatization period, the mice were randomly assigned to one of 
three groups depending on the diet and drug treatment: Group 1, chow-fed mice with vehicle treatment (0.5% 
carboxymethyl cellulose [CMC] solution; Sigma-Aldrich) for 20 weeks (n = 10); Group 2, AMLN-fed mice with 
vehicle treatment for 20 weeks (n = 13); Group 3, AMLN-fed mice with vehicle treatment for 10 weeks followed 
by DPP4i (teneligliptin 20 mg/kg of body weight/day by oral gavage) treatment for 10 weeks (n = 10). The experi-
mental protocol is outlined in Supplementary Figure S1a. Regular chow diet (PicoLab Rodent Diet 20 [5053]) 
contained 23.6% protein, 64.5% carbohydrate, and 11.9% fat (% of total kcal), and the AMNL diet (Catalog 
number D09100301; Research Diets, New Brunswick, NJ, USA) contained 20% protein, 40% high fat (of these 
18% trans-fat), 40% carbohydrates (% of total kcal), and high cholesterol (2% by wt.). Of the total carbohydrate 
content, fructose constituted 22% by weight. The mice were maintained at a temperature of 23 °C ± 2 °C and 
humidity level of 60% ± 10% under a 12-h light/dark cycle.
In all cases, animals were anesthetized and sacrificed 24 h after the final administration. After mice were 
sacrificed, blood was collected via heart puncture and tissues were harvested. Specimens were snap-frozen in 
liquid nitrogen and maintained at − 80 °C until analysis. All animal experiments were approved by the Institu-
tional Animal Care and Use Committee of Yonsei University Health System (YUHS-IACUC) regulations and 
guidelines in accordance with the Animal Protection Act (2008), the Laboratory Animal Act (2008), and the 
Eighth Edition of the Guide for the Care and Use of Laboratory Animals of NRC (2011).
Cell culture and treatment. The human hepatoma cell line HepG2 (American Type Culture Collec-
tion [ATCC], Manassas, VA, USA) was cultured in low glucose Dulbecco’s modified Eagle’s medium (DMEM; 
SH30021.01, HyClone Laboratories, Logan, UT, USA) supplemented with 10% fetal bovine serum, 1% penicil-
lin, and 1% streptomycin in a 5%  CO2 incubator at 37 °C. Cells were incubated in a humidified atmosphere at 
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37 °C and 5%  CO2 and cultured for 3 days to achieve 70% confluence before treatment with palmitate or DPP4i 
(teneligliptin). HepG2 cells were treated with palmitate (Sigma-Aldrich, 0.6 mM) for 18 h with or without pre-
treatment with DPP4i (teneligliptin, 3 μM) for 6 h and were then analyzed. The mRNA and protein expres-
sion levels of DPP4, ER stress, and TRAIL-R2-mediated apoptosis markers were assessed. The mRNA levels 
of collagen1α1 and αSMA, the typical mesenchymal cell markers corresponding to the activated hepatocyte 
state that involves the deposition of extracellular matrix during liver  fibrosis66, were also analyzed. To analyze 
the effect of DPP4i on TRAIL-mediated apoptosis, HepG2 cells were incubated with the recombinant human 
TRAIL/TNFSF10 protein (TRAIL; Cat# 375-TL-010, R&D Systems) at concentrations of 50 and 100 ng/mL for 
18 h, with or without pre-treatment with DPP4i (teneligliptin, 3 μM) for 6 h.
Histology and terminal deoxynucleotidyl transferase dUTP nick‑end labeling (TUNEL) assay 
of the liver tissues. For histological assessment of liver sections under a light microscope (Olympus BX40, 
Olympus Optical Co. Ltd., Tokyo, Japan), 5 mm × 5 mm sections were fixed in 4% paraformaldehyde for 48 h, 
and embedded in paraffin. Tissue Sections (4 μm) were prepared using a microtome (Reichert Scientific Instru-
ments, Buffalo, NY) and placed on glass slides. H&E staining was performed according to the standard pro-
tocols. Liver fibrosis was assessed using the MT staining. The NAFLD activity score and fibrosis stage were 
evaluated in a blinded manner under 200 × magnification according to the scoring system by Kleiner et al.67 The 
TUNEL assay (In Situ Cell Death Detection Kit, Roche, IN, USA) was performed on the paraffin-embedded 
liver sections. To quantify the apoptotic cells, the TUNEL-positive nuclei were counted in a total of 40 random 
microscopic fields (200 × magnification).
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